miércoles, 7 de octubre de 2026

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· April 26, 2026

Is Sanofi (ENXTPA:SAN) Offering Value After Recent Share Price Weakness

View original at finance.yahoo.com

Is Sanofi (ENXTPA:SAN) Offering Value After Recent Share Price Weakness Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide…

Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

Simply Wall St is trusted by over 7 million individual investors worldwide
60% confidence
Analyst and extrapolated forecasts project Sanofi's free cash flow to reach €12.72 billion in 2030, with intermediate annual projections through 2035
60% confidence
Sanofi currently has a value score of 6 out of 6
60% confidence
Sanofi's -9.5% return over the last year is lagging behind its pharmaceutical sector peers
60% confidence
There are 230 or more high quality undervalued stocks available to discover on Simply Wall St's platform
60% confidence
Recent sentiment around Sanofi has been mixed due to broader pharmaceutical sector dynamics, regulatory developments, and shifting investor attention within healthcare
60% confidence
Sanofi is undervalued by 68.7% according to a 2-Stage Free Cash Flow to Equity DCF model, with an estimated intrinsic value of €255.70 per share versus a current price of approximately €80.08
60% confidence

Data points we hold from this source

Sanofi · margin

-68.7 percent

Lo que sabemos · la inteligencia detrás de esta página

En vivo desde el sustrato

Lo que estamos viendo

Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs

Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.

Nuestra lectura de los datos ›

Señales que seguimos

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patrones que observamos ›

Donde las fuentes discrepan

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

Señalamos los conflictos abiertamente ›

Verificado recientemente

✓ Verificado con la fuente original

4,986

hechos rastreados a su fuente — y señalamos los que no se sostienen.

101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados

Consulta estos datos → isubstrate.com